Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by Zacks Investment Research  from a “get” ranking to a “hold” rating in a research note provided to investors on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It focuses on discovering and developing tiny particle drug candidates to deal with cancer cells. The Business‘s products under various stages of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous various other equities research experts also lately talked about the company. Noble Financial reissued a “acquire” ranking as well as provided a $11.00 cost goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and also established a “buy” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. Business has a 50 day relocating typical cost of $2.90 and a two-hundred day relocating typical cost of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly revenues results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) earnings per share for the quarter, topping analysts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and also an adverse net margin of 8,294.27%. The company had earnings of $0.06 million throughout the quarter, compared to the consensus quote of $0.06 million. During the very same quarter in the previous year, the company posted ($ 0.45) EPS. En masse, research analysts forecast that Onconova Therapeutics will certainly upload -1.18 EPS for the existing year.

A variety of hedge funds have recently bought and sold shares of ONTX. GSA Capital Partners LLP purchased a new position in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Funding Monitoring LP bought a new position in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC purchased a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC purchased a new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP got a brand-new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also other institutional investors possess 13.36% of the firm’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It concentrates on discovering as well as creating little molecule drug candidates to deal with cancer cells. The business was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Get a complimentary duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

To learn more about research offerings from Zacks Investment Research, go to Zacks.com.

This instant news alert was generated by narrative science modern technology and financial information from Market in order to provide viewers with the fastest and also most exact reporting. This tale was evaluated by Market’s editorial team before magazine. 

 

SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS TODAY?

Prior to you take into consideration Onconova Therapeutics, you’ll intend to hear this.

Market tracks Wall Street’s premier and best doing research experts and the stocks they recommend to their customers on a daily basis. Market has actually identified the 5 stocks that cover analysts are quietly murmuring to their clients to acquire currently before the wider market catches on … as well as Onconova Therapeutics wasn’t on the list.

While Onconova Therapeutics currently has a “Buy” score among experts, top-rated experts believe these five stocks are better gets.

Related Post